According to information released by changji, the office of the state council recently issued a number of opinions on sound drug price formation mechanisms, aimed at improving market-led drug price formation mechanisms and guaranteeing access to quality and affordable medicines. On 15 april, the press office of the state council held a policy briefing, during which the national health and safety service and the national drug authority, among others, presented relevant reform initiatives。
The opinions present a range of reform initiatives across the board, through channels and across areas. On the whole, the price policy has been improved in accordance with the different stages of the drug market, leaving room for a high level of quality and leading to fair and reasonable pricing of other medicines. On the whole, all parties are encouraged to participate in the price formation of medicines, to promote transparency and transparency of information on the price of medicines in different channels, and to facilitate comparison of choices among the population. In all areas, the pricing, supply, payment, etc. Of medicines in key areas is regulated to improve their accessibility。
In support of development, the opinion suggests precision measures. Data from the national drug authority show that the average time taken for clinical trials was 71 per cent lower than during the “1355” period. The national health insurance board noted that, as of february this year, the health insurance fund had spent a total of 50. 4 billion yuan on the negotiation of medicines during the agreement period, benefiting 1. 17 billion people. Specific measures include: exploring the optimization of initial pricing mechanisms at the initial stage of the drug, supporting high-level stabilization of prices commensurate with high input, high-risk risks; rationalizing the clinical value of the drug in the health-care catalogue adjustment; and clarifying that centralized lead procurement does not involve “innovation and non-innovation”。
In order to further improve the mechanisms for the pricing of medicines, the national health service will optimize the rules for the collection of medicines, improve the rules for the procurement of chemicals, biopharmaceuticals, etc., and use a variety of methods to guide enterprises to rational competition. At the same time, the result of the selection is reinforced by giving priority to the use of the selected product in medical institutions and allowing the use of other non-selective products to avoid a “one-size-fits-all”. In addition, inter-provincial collection models will be encouraged to raise the level of standardization of harvesting。
Our drug supply security capacity continues to be consolidated. According to the ministry of industry and information technology, our country has about 160,000 approved medicines and can produce a full range of pharmaceutical products. Innovation capacity has increased significantly, accounting for about one third of the world's research. The industrial base continues to be consolidated and the advantages of integration with agents have expanded, with the country holding six seats in the world's top 50 pharmaceutical enterprises. More resilient supply security and a well-developed national pharmaceutical reserve system have effectively eased the supply of more than 130 essential clinical drugs。
In the area of quality control, the national agency for medicines has “full coverage” of selected enterprises and varieties for testing, and the overall pass rate for drugs has remained at over 99 per cent. Market regulators will vigorously combat prices and monopolistic offences in the field of medicines, safeguarding market order and the legitimate rights and interests of the population in the use of medicines。
